Business Overview: Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY)

---

Executive Summary

Harmony Biosciences Holdings, Inc. is a neuroscience company focused on rare neurological diseases, organized around three franchises: sleep/wake, neurobehavioral, and rare epilepsy.

Harmony matters because its sole approved product, WAKIX® (pitolisant), holds a distinctive regulatory position: it is, in the company's own words, the only FDA-approved narcolepsy treatment that is not scheduled as a controlled substance by the DEA — a real commercial and prescribing advantage in a category otherwise dominated by scheduled drugs.

---

1. Core Business Model & How They Work

Harmony earns revenue almost entirely from WAKIX net product sales, while investing heavily in a pipeline of additional rare-neurological-disease candidates licensed or acquired from external partners.

[ License/Acquire Rare-Disease Candidates ] ➡️ [ Clinical Development (Phase 2/3) ] ➡️ [ FDA Approval ] ➡️ [ Commercialize via Specialty Pharmacy Network ] ➡️ [ Reinvest Cash Flow into Pipeline Expansion ]

Key operational drivers:

1. Single approved product funding a broad pipeline — WAKIX generated $714.7 million in net product revenue in FY2024, funding development across six additional disease programs.
2. Licensing-driven pipeline strategy — rather than relying solely on internal discovery, Harmony has licensed key assets from Bioprojet (pitolisant, next-gen formulations, an orexin agonist) and acquired Zynerba for ZYN-002.
3. Extreme specialty-pharmacy concentration — Caremark, Accredo, and PANTHERx together represent 100% of gross WAKIX product revenue (39%, 34%, and 27% respectively), making distribution channel relationships critical.
4. Rare-disease-by-rare-disease expansion — rather than entering broad neurology, Harmony targets specific orphan-sized patient populations (idiopathic hypersomnia, Prader-Willi syndrome, myotonic dystrophy type 1, Fragile X, 22q deletion syndrome, Dravet and Lennox-Gastaut syndromes).

---

2. Business Segments

Harmony does not report formal reportable segments; its 10-K organizes the business by therapeutic franchise:

Sleep/Wake (commercial + pipeline)

WAKIX (approved, $714.7M FY2024 revenue) plus pipeline programs in idiopathic hypersomnia, Prader-Willi syndrome, and myotonic dystrophy type 1, along with next-generation pitolisant formulations (GR, HD) and an orexin 2 receptor agonist (BP1.15205).

Neurobehavioral (pipeline)

ZYN-002 (cannabidiol gel), acquired with Zynerba in October 2023, in Phase 3 development for Fragile X syndrome and planned for 22q deletion syndrome.

Rare Epilepsy (pipeline)

EPX-100 (clemizole) in Phase 3 for Dravet syndrome, with planned expansion into Lennox-Gastaut syndrome, and EPX-200 in early-stage development.

---

3. Product Portfolio

---

4. Competitive Landscape

Narcolepsy (WAKIX):

• Jazz Pharmaceuticals — Xyrem and Xywav (Schedule III), plus generic sodium oxybate competitors (Hikma, Amneal).
• Avadel — Lumryz, a once-nightly sodium oxybate formulation.
• Stimulants/wakefulness agents — Provigil, Nuvigil, methylphenidate, amphetamine, and Axsome's Sunosi.
• Pipeline threats — Axsome (AXS-12), Suven, NLS Pharmaceutics, and orexin agonists from Takeda, Jazz/Sumitomo, Centessa, and Alkermes.
• Harmony notes WAKIX is priced below sodium oxybate products but above modafinil/armodafinil/generic stimulants, without head-to-head trial comparisons.

Other franchises: PWS (Acadia, Soleno, Rhythm, Palobiofarma); DM1 (Avidity, Vertex, Entrada, PepGen); FXS (Acadia, Mirum, Spinogenix); 22q (Nobias); rare epilepsy (GW/Lundbeck, Biocodex, Eisai approved; Supernus, SK Life Science, Stoke in development).

---

5. Strategic Strengths & Risks

Strengths

• WAKIX's unique non-scheduled status is a genuine prescribing differentiator in a category where scheduled-drug stigma and DEA scrutiny matter to physicians and patients.
• Diversified, multi-franchise pipeline (sleep/wake, neurobehavioral, rare epilepsy) reduces long-term dependence on a single disease area.
• Strong existing cash generation from WAKIX funds pipeline investment without requiring external dilutive financing for every program.
• Licensing relationship with Bioprojet has already produced one approved, large-revenue product and offers further formulations (GR, HD) to extend that franchise's commercial life.

Risks

• Near-total product concentration — WAKIX is effectively Harmony's only revenue source today; any competitive, regulatory, or reimbursement setback to that single product disproportionately affects the whole company.
• Extreme specialty pharmacy concentration — Caremark, Accredo, and PANTHERx represent 100% of gross product revenue between them, a significant channel concentration risk.
• The idiopathic hypersomnia program suffered a real setback: the FDA issued a Refusal to File letter in February 2025 after the INTUNE Phase 3 trial's primary endpoint was not statistically significant.
• Harmony relies on single-source API suppliers for WAKIX and each pipeline candidate, creating supply-chain concentration risk.
• A deep, well-funded competitive pipeline (Takeda, Jazz/Sumitomo, Centessa, Alkermes in orexin agonists) could erode WAKIX's narcolepsy position over the long term.

---

6. Financial Overview

---

7. Summary Conclusion

Harmony Biosciences has built a profitable, cash-generative base around WAKIX's genuinely differentiated position as the only non-scheduled narcolepsy drug, and it is using that cash flow to fund a diversified pipeline across three rare-neurological-disease franchises rather than resting on a single product. That diversification strategy is sound in principle, but today's reality is that Harmony remains almost entirely dependent on one drug sold through three concentrated specialty pharmacy partners, and its most advanced pipeline diversification effort (idiopathic hypersomnia) has already hit a real regulatory setback. The company's path to reducing WAKIX-concentration risk runs through successfully advancing its FXS, PWS, DM1, and rare epilepsy programs into approved, commercially meaningful products.